

Genzyme Corporation (GENZ)

Analyst Schedule

(Unaudited, amounts in thousands, except percentage amounts)

	Q3-08	Q4-08	Q1-09	Q2-09	Q3-09	Q4-09	Q4-09 vs. Q4-08 % B/(W)	FY 2007	FY 2008	YTD 12/31/09
Total revenues:										
Genetic Diseases										
Cerezyme	\$ 309,280	\$ 306,034	\$ 295,970	\$ 298,087	\$ 93,599	\$ 105,368	(66%)	\$ 1,133,153	\$ 1,238,977	\$ 793,024
Fabrazyme	125,619	125,558	122,201	134,302	115,161	58,026	(54%)	424,284	494,260	\$ 429,690
Myozyme	76,663	74,967	67,392	79,273	85,980	91,900	23%	200,728	296,176	324,545
Aldurazyme	38,236	37,579	36,837	39,190	40,331	38,707	3%	-	151,664	155,065
Other Genetic Diseases	11,367	14,039	14,650	17,301	19,217	21,052	50%	8,314	45,615	72,220
Total Genetic Diseases product and service revenue	561,165	558,177	537,050	568,153	354,288	315,053	(44%)	1,766,479	2,226,692	1,774,544
R&D Revenue	-	-	-	-	-	-		1,059	-	-
Total Genetic Diseases	561,165	558,177	537,050	568,153	354,288	315,053	(44%)	1,767,538	2,226,692	1,774,544
Cardiomatabolic and Renal										
Renagel and Renvela (including Sevelamer)	170,992	169,476	170,599	175,398	181,702	178,890	6%	602,670	677,729	706,589
Hectorol	33,825	34,400	33,030	28,981	36,869	31,877	(7%)	115,708	128,153	130,757
Subtotal	204,817	203,876	203,629	204,379	218,571	210,767	3%	718,378	805,882	837,346
Thyrogen	38,153	37,062	38,826	42,860	41,691	47,267	28%	113,587	148,448	170,644
Other Cardiomatabolic and Renal	573	496	494	753	742	1,027	107%	103	1,653	3,016
Total Cardiomatabolic and Renal product and service revenue	243,543	241,434	242,949	247,992	261,004	259,061	7%	832,068	955,983	1,011,006
R&D revenue	56	27	13	8	156	155	474%	1,200	200	332
Total Cardiomatabolic and Renal	243,599	241,461	242,962	248,000	261,160	259,216	7%	833,268	956,183	1,011,338
Biosurgery										
Synvisc	67,513	68,512	63,171	82,417	87,526	95,419	39%	242,319	263,094	328,533
Sepra products	33,001	35,278	34,304	36,038	37,831	40,365	14%	104,318	133,663	148,538
Other Biosurgery	21,787	20,908	21,485	20,002	19,643	21,121	1%	74,673	91,698	82,251
Total Biosurgery product and service revenue	122,301	124,698	118,960	138,457	145,000	156,905	26%	421,310	488,455	559,322
R&D revenue	661	563	562	870	647	414	(26%)	5,337	2,645	2,493
Total Biosurgery	122,962	125,261	119,522	139,327	145,647	157,319	26%	426,647	491,100	561,815
Hematologic Oncology										
Total Hematologic Oncology product and service revenue	26,328	27,437	34,423	55,078	87,982	108,117	294%	69,927	102,899	285,600
R&D revenue	7,726	15,104	8,775	5,918	7	134	(99%)	18,601	36,148	14,834
Total Hematologic Oncology	34,054	42,541	43,198	60,996	87,989	108,251	154%	88,528	139,047	300,434
Other										
Genetic/Diagnostics product and service revenue	121,163	124,840	129,194	132,955	133,748	142,340	14%	410,917	477,614	538,237
Transplant product and service revenue	47,784	50,723	52,666	56,060	55,604	60,623	20%	174,826	192,200	224,953
Other product and service revenue	28,598	30,252	23,501	22,423	18,496	37,101	23%	108,577	119,155	101,521
Total Other product and service revenue	197,545	205,815	205,361	211,438	207,848	240,064	17%	694,320	788,969	864,711
R&D revenue	959	305	778	596	582	727	138%	3,218	3,048	2,683
Total Other	198,504	206,120	206,139	212,034	208,430	240,791	17%	697,538	792,017	867,394
Total revenues	\$ 1,160,284	\$ 1,173,560	\$ 1,148,871	\$ 1,228,510	\$ 1,057,514	\$ 1,080,630	(8%)	\$ 3,813,519	\$ 4,605,039	\$ 4,515,525

All amounts herein are presented in accordance with GAAP and are provided for quantitative analysis only and should be read in conjunction with the text of the Earnings Release and our audited financial statements filed with the Securities and Exchange Commission. Please refer to our Form 10-Q's and Form 10-K's for an in-depth discussion and analysis of our results of operations and financial position and for detailed information regarding specific material transactions in a particular period.